This page shows the latest liposomal irinotecan news and features for those working in and with pharma, biotech and healthcare.
The Dublin-based company said the deal covers its already-marketed drug Oncaspar (pergaspargase) for acute lymphoblastic leukaemia (ALL), as well as ex-US rights to pancreatic cancer therapy Onivyde (irinotecan ... pegylated liposomal formulation) and
NICE has ruled that Shire’s pancreatic cancer drug Onivyde (pegylated liposomal irinotecan) is not a cost-effective use of NHS resources. ... NICE said in a statement: “Although this analysis was subject to considerable uncertainty, the committee was
The deal includes Onivyde (liposomal irinotecan) and Merrimack's generic version of Doxil (liposomal doxorubicin), as well as the manufacturing and commercial operations supporting the two products.
EU. Authorised as a second-line combination therapy, Onivyde (pegylated liposomal irinotecan hydrochloride trihydrate) will be administered with 5-fluorouracil (5-FU) and leucovorin (LV) in adult patients who have progressed
The CHMP also gave a positive opinion for Shire's Onivyde (pegylated irinotecan liposomal formulation) for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin,
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
At the start of this year it acquired Merrimack’s oncology business, including Onivyde (liposomal irinotecan), for $575m.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...